{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:47:19Z","timestamp":1792392439740,"version":"4.4.0"},"reference-count":53,"publisher":"Impact Journals, LLC","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,27]]},"DOI":"10.18632\/oncotarget.21113","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T17:40:12Z","timestamp":1506015612000},"page":"89722-89735","source":"Crossref","is-referenced-by-count":53,"title":["Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients"],"prefix":"10.18632","volume":"8","author":[{"given":"Elly","family":"Marcq","sequence":"first","affiliation":[{"name":"Center for Oncological Research, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorrit De","family":"Waele","sequence":"additional","affiliation":[{"name":"Center for Oncological Research, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Van","family":"Audenaerde","sequence":"additional","affiliation":[{"name":"Center for Oncological Research, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lion","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Santermans","sequence":"additional","affiliation":[{"name":"Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niel","family":"Hens","sequence":"additional","affiliation":[{"name":"Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium"},{"name":"Center for Health Economics Research and Modelling Infectious Diseases, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Pauwels","sequence":"additional","affiliation":[{"name":"Center for Oncological Research, University of Antwerp, Antwerp, Belgium"},{"name":"Department of Pathology, Antwerp University Hospital, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"van Meerbeeck","sequence":"additional","affiliation":[{"name":"Center for Oncological Research, University of Antwerp, Antwerp, Belgium"},{"name":"Thoracic Oncology\/MOCA, Antwerp University Hospital, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien L.J.","family":"Smits","sequence":"additional","affiliation":[{"name":"Center for Oncological Research, University of Antwerp, Antwerp, Belgium"},{"name":"Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,9,21]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Lake","year":"2005","journal-title":"Lancet"},{"key":"2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","article-title":"The worldwide pandemic of asbestos-related diseases","volume":"34","author":"Lemen","year":"2013","journal-title":"Annu Rev Public Health"},{"key":"3","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Lake","year":"2005","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"Giaccone","year":"2005","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Paoletti","year":"2003","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11864-011-0149-1","article-title":"Novel targeted therapies and vaccination strategies for mesothelioma","volume":"12","author":"Nowak","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2012.02.034","article-title":"Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies","volume":"322","author":"Bei","year":"2012","journal-title":"Cancer Lett"},{"key":"8","doi-asserted-by":"publisher","first-page":"927240","DOI":"10.1155\/2012\/927240","article-title":"New roads open up for implementing immunotherapy in mesothelioma","volume":"2012","author":"Hegmans","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","author":"van Brummelen","year":"2017","journal-title":"Lancet Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Maio","year":"2013","journal-title":"Lancet Oncol"},{"key":"11","first-page":"5s","article-title":"A phase 2 single-arm study with tremelimumab at an optimized doseing schedule in second-line mesothelioma patients","volume":"32","author":"Maio","year":"2014","journal-title":"J ClinOncol"},{"key":"12","first-page":"34","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression","author":"Delord","year":"2016","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"A phase II study of Nivolumab in malignant pleural mesothelioma (NIVOMES): with translational research (TR) biopsies","volume":"12","author":"Baas","year":"2017","journal-title":"J Thor Oncol"},{"key":"14","first-page":"5s","article-title":"Randomized, double-blind, placebo-controlled study of tremelimumab for second and third-line treatment of unresectable pleural or peritoneal mesothelioma","volume":"32","author":"Kindler","year":"2014","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Smits","year":"2017","journal-title":"Oncoimmunology"},{"key":"16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1164\/rccm.201203-0465PP","article-title":"Malignant pleural effusion: tumor-host interactions unleashed","volume":"186","author":"Kalomenidis","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"17","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","article-title":"Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages","volume":"11","author":"Blanquart","year":"2016","journal-title":"J Thorac Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab","volume":"11","author":"Hassan","year":"2016","journal-title":"J Thorac Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression","volume":"11","author":"Aerts","year":"2016","journal-title":"J Thorac Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/1471-2407-13-324","article-title":"Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid","volume":"13","author":"Labalette","year":"2013","journal-title":"BMC Cancer"},{"key":"21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/82_2010_114","article-title":"LAG-3 in Cancer Immunotherapy","volume":"344","author":"Drake","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1365-2567.2005.02145.x","article-title":"The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells","volume":"115","author":"Triebel","year":"2005","journal-title":"Immunology"},{"key":"23","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","article-title":"Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)","volume":"174","author":"Vignali","year":"2005","journal-title":"J Immunol"},{"key":"24","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Smyth","year":"2011","journal-title":"Cancer Res"},{"key":"25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/CJI.0b013e318183af0b","article-title":"Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients","volume":"31","author":"Zarour","year":"2008","journal-title":"J Immunother"},{"key":"26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Kuchroo","year":"2002","journal-title":"Nature"},{"key":"27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1126\/science.1148536","article-title":"Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells","volume":"318","author":"Kuchroo","year":"2007","journal-title":"Science"},{"key":"28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/dc.21340","article-title":"Podoplanin is a useful marker for identifying mesothelioma in malignant effusions","volume":"38","author":"Michael","year":"2010","journal-title":"Diagn Cytopathol"},{"key":"29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1440-1827.2005.01791.x","article-title":"Podoplanin as a marker for mesothelioma","volume":"55","author":"Kimura","year":"2005","journal-title":"Pathol Int"},{"key":"30","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3892\/or.2013.2225","article-title":"Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype","volume":"29","author":"Kuwano","year":"2013","journal-title":"Oncol Rep"},{"key":"31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/cas.13190","article-title":"Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation","volume":"108","author":"Yano","year":"2017","journal-title":"Cancer Sci"},{"key":"32","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Kwon","year":"2014","journal-title":"J Thorac Oncol"},{"key":"33","doi-asserted-by":"publisher","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Felip","year":"2015","journal-title":"PLoS One"},{"key":"34","doi-asserted-by":"publisher","first-page":"e0167186","DOI":"10.1371\/journal.pone.0167186","article-title":"Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis","volume":"11","author":"Tsuchida","year":"2016","journal-title":"PLoS One"},{"key":"35","doi-asserted-by":"publisher","first-page":"7898","DOI":"10.4049\/jimmunol.0901060","article-title":"Dual control of antitumor CD8 T cells through the programmed death-1\/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation","volume":"183","author":"van der Most","year":"2009","journal-title":"J Immunol"},{"key":"36","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Nishimura","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"37","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Tokura","year":"2010","journal-title":"Cancer"},{"key":"38","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Fujii","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"39","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Cheville","year":"2006","journal-title":"Cancer Res"},{"key":"40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ctrv.2015.09.006","article-title":"Targeting immune checkpoints: New opportunity for mesothelioma treatment?","volume":"41","author":"Smits","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/1097-0142(19840201)53:3<377::AID-CNCR2820530302>3.0.CO;2-B","article-title":"Malignant mesothelioma. The University of Minnesota experience","volume":"53","author":"Kennedy","year":"1984","journal-title":"Cancer"},{"key":"42","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1084\/jem.176.2.327","article-title":"Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens","volume":"176","author":"Piatier-Tonneau","year":"1992","journal-title":"J Exp Med"},{"key":"43","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/eji.200323382","article-title":"The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells","volume":"33","author":"Vignali","year":"2003","journal-title":"Eur J Immunol"},{"key":"44","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","article-title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9","volume":"119","author":"Blazar","year":"2012","journal-title":"Blood"},{"key":"45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1183\/16000617.0019-2016","article-title":"Malignant pleural effusion: from bench to bedside","volume":"25","author":"Stathopoulos","year":"2016","journal-title":"Eur Respir Rev"},{"key":"46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lungcan.2016.04.015","article-title":"Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients","volume":"107","author":"Aerts","year":"2017","journal-title":"Lung Cancer"},{"key":"47","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults","volume":"112","author":"Paul","year":"2008","journal-title":"Blood"},{"key":"48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cytogfr.2012.08.009","article-title":"The emerging role of T cell cytokines in non-small cell lung cancer","volume":"23","author":"Finotto","year":"2012","journal-title":"Cytokine Growth Factor Rev"},{"key":"49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/CJI.0b013e31825898c5","article-title":"Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes","volume":"35","author":"Dudley","year":"2012","journal-title":"J Immunother"},{"key":"50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Sharpe","year":"2010","journal-title":"Immunol Rev"},{"key":"51","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.4049\/jimmunol.1002050","article-title":"MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis","volume":"186","author":"Michel","year":"2011","journal-title":"J Immunol"},{"key":"52","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"Adusumilli","year":"2014","journal-title":"Clin Cancer Res"},{"key":"53","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Wolchok","year":"2010","journal-title":"J Natl Cancer Inst"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:36:04Z","timestamp":1719462964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,21]]},"references-count":53,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2017,10,27]]}},"alternative-id":["21113","29163783"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.21113","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,21]]}}}